Eli Lilly said on Thursday its experimental pill, orforglipron, led to a weight loss of nearly 8% at the highest dose and lowered blood sugar for overweight patients with Type 2 diabetes in a late-stage trial. Shares of the company jumped nearly 13% in premarket......
[Full Story]